Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.49 |
| ▸ | PDE2A | O00408 | 6/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248717 | 0.90 | DGAT1 (0.48) | ACSS2PDE2ANPC1RAB9AKMT2A | |
| SCHEMBL1250473 | 0.88 | ESR2 (0.49) | PDE2APDE10AESR2NPC1RAB9A | |
| SCHEMBL1249228 | 0.85 | RAB9A (0.48) | ACSS2NPC1RAB9AKMT2AMCHR1 | |
| SCHEMBL1249330 | 0.85 | DGAT1 (0.56) | ACSS2NPC1RAB9AKMT2ADGAT1 | |
| SCHEMBL1250558 | 0.83 | MAPT (0.46) | ACSS2NPC1RAB9AKMT2ADGAT1 | |
| SCHEMBL3171773 | 0.81 | PTGER4 (0.48) | ACSS2PDE2APDE10AESR2KMT2A | |
| SCHEMBL1249925 | 0.81 | DGAT1 (0.47) | ACSS2NPC1RAB9AKMT2ADGAT1 | |
| SCHEMBL1250370 | 0.79 | DGAT1 (0.53) | PDE2ANPC1RAB9AKMT2ADGAT1 | |
| SCHEMBL1248696 | 0.73 | PRSS12 (0.60) | NPC1RAB9AKMT2ADGAT1SMN1; SMN2 | |
| SCHEMBL1250280 | 0.73 | DGAT1 (0.61) | NPC1RAB9AKMT2ADGAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | ACSS2 128/4885PDE2A 2882/4885PDE10A 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.